Archive for the ‘News’ Category

Anaeropharma Science Announces Closing of Financing

TOKYO, July 5, 2017

Anaeropharma Science, Inc., a company dedicated to the development of novel therapeutics to target hypoxic solid tumors, announced on July 5 it has secured US$13.2 million in new capital. The participants in the financing round include three new investors, Novartis, Shinsei Corporate Investment Limited and Seventure Partners’ Health for Life Capital fund, and two existing investors, Innovation Network Corporation of Japan and Mitsubishi UFJ Capital’s managed fund. Anaeropharma will use the financing to accelerate the development of multiple programs based on its proprietary platform technology.

About Anaeropharma Science, Inc.

Anaeropharma is a biopharmaceutical company engaged in research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant Bifidobacterium. This approach offers broad potential to be more effective to solid tumors and less toxic to healthy tissues than conventional anti-cancer drugs. APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is its leading development product which is under a clinical trial in the U.S., and additional programs in the immune oncology area such as immune checkpoint blockers and other immune-related molecules expressing recombinant Bifidobacteria are under active development.

PDF download here

Anaeropharma Science will be presenting its latest research outcomes at the 2017 Annual Meeting of the AACR

Anaeropharma Science will be presenting its latest research outcomes towards combination approaches of its i-DPS therapy with immune checkpoint inhibitor at the 2017 Annual Meeting of the AACR (American Association for Cancer Research), which takes place from April 1st to the 5th in Washington D.C.

The first poster is titled “Synergistic anti-tumor efficacy of combination therapy with APS001F, a cytosine deaminase (CD) expressing Bifidobacterium, 5-fluorocytosine (5-FC) and anti-mPD-1 antibody in syngeneic mice model”, which will be presented on Apr. 4th, from 1:00 PM to 5:00 PM, in the session of Clinical Immunotherapy, Viruses, and Bacteria.

PDF download here

The second one is titled “Enhanced anti-tumor effects by a combination approach of interferon-γ producing recombinant Bifidobacterium and anti-mPD-1 antibody in CT26 syngeneic mouse model”, which will be presented on Apr. 3rd, from 1:00 PM to 5:00 PM, in the session of Checkpoints 2: Small-Molecule Inhibitors.

PDF download here

Anaeropharma will present new research outcomes at AACR Conference on Tumor Immunology and Immunotherapy

At upcoming AACR Special Conference on Tumor Immunology and Immunotherapy taking place October 20-23, 2016 in Boston, MA, Anaeropharma will present its new research outcomes regarding cancer immunotherapy titled “Anti-CTLA-4 antibody scFv producing recombinant Bifidobacterium secretes CTLA-4 blocker specifically inside hypoxic tumor and suppresses tumor growth in syngeneic mice model”.

PDF download here

Anaeropharma has presented at 20th JFCR-ISCC (Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy)

At 20th JFCR-ISCC held in December 2015, Anaeropharma has presented its progress on immune checkpoint blocker producing B. longum which titled in “i-DPS (in situ Delivery and Production System): A “smart” Drug Delivery System to Produce Immune Checkpoint Blockers inside Hypoxic Tumor”.

Anaeropharma has presented at BioJapan2015

Anaeropharma has presented its technology platform at BioJapan2015 held in October.

Anaeropharma has presented at JCA (Japanese Cancer Association) Annual Meeting 2015

Anaeropharma has presented its recent research progress which titled in “In situ Delivery and Production System (i-DPS) of Immune Checkpoint Blockers Targeting Tumor Microenvironment” at the annual meeting of JCA held in October, 2015.

Anaeropharma has presented at AACR (American Association for Cancer Research) Annual Meeting 2015

At the annual meeting of AACR held in April 2015, Anaeropharma has presented two posters as follows; 1. In situ delivery and production of anti-HER2 scFv, poster #290. 2. Novel delivery system to bring immune checkpoint antibodies to tumor microenvironment, poster #282.

Presenting our latest research updates at PEGS2014 poster sessions

We are presenting our latest research updates at PEGS2014 poster sessions. PEGS2014 is scheduled to be held in Boston, MA from May 5-9, 2014.

Click here for detail.

Initiated First-in-Human Trial of Novel Recombinant Bifidobacterial Anti-cancer Agent APS001F for Advanced Solid Tumors

We have initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent.


We have updated Research Overview Page

see here for detail.